DARWIN EU® - Assessing the feasibility of conducting a causal study on the potential association between beta-blockers and breast cancer

02/06/2026
02/06/2026
EU PAS number:
EUPAS1000001013
Study
Ongoing
Subscribe
Download as PDF
Study summary
No information provided.
Study identification

EU PAS number

EUPAS1000001013

Study ID

1000001013

Official title and acronym

DARWIN EU® - Assessing the feasibility of conducting a causal study on the potential association between beta-blockers and breast cancer

DARWIN EU® study

Yes

Study countries

Denmark
Norway
Spain
Sweden
United Kingdom

Study description

Hypertension is highly prevalent in adult women and commonly requires long-term use of antihypertensive medications. Long-term use of antihypertensive medications raises concerns about potential adverse effects, including cancer risk.
Beta-blockers have been used for decades to treat hypertension. Beyond cardiovascular effects, beta-adrenergic signalling may influence cancer-related processes, which could affect breast cancer development. However, prior observational evidence is inconsistent, likely due to confounding by indication and design differences. Β1-selective beta-1 agents differ from non-selective agents, yet many studies have evaluated beta-blockers as a single class.
This feasibility study assesses whether selected data sources in the DARWIN EU® Data Network can support robust causal research on a comparative safety of beta-blockers in relation to incident breast cancer.

Study status

Ongoing
Research institutions and networks

Institutions

Networks

Contact details

Yuqing Hu

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
EMA
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable